- INCOG BioPharma Services is investing approximately $200 million to expand injectable drug product manufacturing at its Fishers, Indiana facility.
- The expansion is expected to support up to 480 million units per year and employ nearly 1,000 people by 2030.
INCOG BioPharma Services has announced an expansion of its manufacturing operations with an investment of approximately $200 million at its facility in Fishers, Indiana. The company operates as a contract development and manufacturing organisation (CDMO) providing contract manufacturing services for injectable drug products.
The investment is intended to significantly increase injectable drug product manufacturing capacity at the site. The expansion is scheduled to begin in early 2026 and will establish a 21-acre campus with around 300,000 square feet of purpose-built manufacturing space focused on injectable biopharmaceuticals.
INCOG said the expanded facility will include advanced manufacturing infrastructure supporting sterile fill and finish, automated inspection, device assembly, labelling, serialization and final packaging. Once complete, the site is expected to be capable of producing up to 480 million units per year, allowing the company to serve a larger share of global demand for injectable drug products.
By 2030, the company expects to employ nearly 1,000 people at the Fishers campus across functions including operations, engineering, quality and administration. The investment is supported by incentives from the State of Indiana and builds on INCOG’s long-standing partnership with the City of Fishers.
“The continued demand from our global biopharma partners and our team’s ability to deliver create the opportunity for this next level of investment and expansion.”
Cory Lewis, CEO of INCOG BioPharma
